THE HIV LIFE CYCLE. Understanding How Antiretroviral Medications Work

Similar documents
HIV Drugs and the HIV Lifecycle

HIV MEDICATIONS AT A GLANCE. Atripla 600/200/300 mg tablet tablet daily. Complera 200/25/300 mg tablet tablet daily

HIV medications HIV medication and schedule plan

WOMENS INTERAGENCY HIV STUDY ANTIRETROVIRAL DOSAGE FORM SECTION A. GENERAL INFORMATION

WOMEN'S INTERAGENCY HIV STUDY METABOLIC STUDY: MS01 SPECIMEN COLLECTION FORM

Antiretroviral Dosing in Renal Impairment

October 26-28: Training Day 1

Northwest AIDS Education and Training Center Educating health care professionals to provide quality HIV care

0.14 ( 0.053%) UNAIDS 10% (94) ( ) (73-94/6 ) 8,920

HIV THERAPY STRATEGIES FOR THIRD LINE. issues to consider when faced with few drug options

MEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 03/07/18 SECTION: DRUGS LAST REVIEW DATE: 02/19/19 LAST CRITERIA REVISION DATE: ARCHIVE DATE:


Daclatasvir (Daklinza ) Drug Interactions with HIV Medications

Nothing to disclose.

ANTIRETROVIRAL TREATMENTS (Part 1of

Fluconazole dimenhydrinate, diphenhydramine. Raltegravir or dolutegravir with antacids

Human Immunodeficiency Virus (HIV) and Acquired Immune Deficiency Syndrome (AIDS) in the Long Term Care Setting Part 2: HIV Medications

Antiretrovial Crushable/Liquid Formulation Chart

ALABAMA S ADAP FORMULARY OFFERS 117 MEDICATIONS

BHIVA ART Guideline 2014 update: SEARCH PROTOCOL: main databases search

REIMBURSEMENT STATUS OF HIV MEDICATIONS IN ONTARIO

HIV Management Update 2015

Nobel /03/28. HIV virus and infected CD4+ T cells

Drug Treatment Program Update

ADAP Monitoring Provider Prescribing Patterns. Amanda Bowes, NASTAD Christine Rivera and Dr. Charles Gonzalez, NYS AIDS Institute

An HIV Update Jan Clark, PharmD Specialty Practice Pharmacist

The ART of Antiretroviral Therapy in Critically-ill Patients with HIV

continuing education for pharmacists

Industry Data Request

HIV Pharmacology 101ish - 202ish: New HIV Clinicians Workshop

HIV THERAPY STRATEGIES FOR FIRST LINE. issues to think about when going on therapy for the first time

COMPREHENSIVE ANTIRETROVIRAL TABLE: ADULT DOSING, DOSAGE FORM MODIFICATIONS, ADVERSE REACTIONS and INTERACTION POTENTIAL

Appropriate Use & Safety Edits

Approach for the Newly Diagnosed HIV Positive Patient

HIV Infection & AIDS in Low- and Middle-Income Countries

JULUCA (dolutegravir sodium-rilpivirine hydrochloride) oral tablet

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 9 May 2012

COMPREHENSIVE ANTIRETROVIRAL TABLE: ADULT DOSING**, DOSAGE FORM MODIFICATIONS, ADVERSE REACTIONS and INTERACTION POTENTIAL

Midwestern Underwriting Conference 2016

FORMULARY Virginia (VA) AIDS Drug Assistance Program (ADAP) LAST UPDATED: December At a Glance: VA ADAP Formulary

Addressing Pediatric Needs of the Most Neglected: next steps

Simplifying HIV Treatment Now and in the Future

Risk of HIV-1 low level viremia to treatment. Germany. Nadine Lübke Düsseldorf

MEDICATION RELATED ISSUES IN THE HIV PATIENT. LEONARD SOWAH, MBChB, MPH, FACP

HIV and YOU. Special 2008 Update!

A Fatal Imbalance. Tropical diseases: 18 new drugs (incl. 8 for malaria) 1.3% 21 new drugs for neglected diseases. Tuberculosis: 3 new drugs

FLORIDA!A MEDICAID' Better Health Care for all Floridians. May

Principles of HIV Drug Resistance: Resistance to New Drug Classes. Mark A Wainberg McGill University AIDS Centre Montreal, Quebec, Canada

Approach to a Patient Newly Diagnosed with HIV, Including ART Basics Rajesh T. Gandhi, M.D.

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 3 November 2010

Industry Request Integrase Inhibitors

Medscape's Antiretroviral Pocket Guide for the Treatment of HIV Infection

Human Immunodeficiency Virus Infection A Modern Day Epidemic

Objectives. HIV Treatment in Recently In 1996 the introduction of protease inhibitors decreasing the death rate of those infected by 50%.

ACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals

New Frontiers for Treatment Strategies for HIV Care

P.I. Perspective. December 2008, Issue #47. Information, Inspiration and Advocacy for People Living with HIV/AIDS

Human Immunodeficiency Virus (HIV)

Matters of the HAART: An Update on Current Treatment Options for HIV

Antiretroviral Pregnancy Registry

Overview of HIV WRAIR- GEIS 'Operational Clinical Infectious Disease' Course

OB/GYN CHART REVIEW DRAFT: NOT FOR DISTRTIBUTION

30 Years of HIV: An Update on Treatment Guidelines and Beyond

HIV Today: Examining the Latest Treatment Advances, Barriers to Care, and Pharmacists Implications

Selecting an Initial Antiretroviral Therapy (ART) Regimen

PHARMACOKINETICS OF ANTIRETROVIRAL AND ANTI-HCV AGENTS

Sculpting a Better Regimen: The ART of HIV Medications

PROGRESSIVE MULTI-FOCAL LEUKOENCEPHALOPATHY

treatment passport 1

Overview of HIV. LTC Paige Waterman

World AIDS Day Year-by-Year Milestones in HIV/AIDS. healthlibrary

HIV Integrase Inhibitors: Current and Future Use. Douglas G. Fish, MD Albany Medical College Cali, Colombia March 13, 2008

HIV/AIDS Update 2007

NON-OCCUPATIONAL POST EXPOSURE PREVENTION. when you think you were exposed to hiv within the past three days

HIV Update. Divya Ahuja, MD Associate Professor of Medicine University of South Carolina School of Medicine

Medication Errors Focus on the HIV-Infected Patient

Second-Line Therapy NORTHWEST AIDS EDUCATION AND TRAINING CENTER

Continuing Education for Pharmacy Technicians

HIV in the United States: At A Glance

Outline Epidemiology: Global and U.S. How are we doing in terms of goals of treatment? Updates in the fast moving field of HIV medicine EPIDEMIOLOGY

Genotyping and Drug Resistance in Clinical Practice. Case Studies

TRANSPARENCY COMMITTEE

HIV Drug Market by Medication class (multi-class combination drugs, nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse

Terapia antirretroviral inicial y de rescate: Utilidad actual y futura de nuevos medicamentos

The Future of HIV: Advances in Drugs and Research. Shauna Gunaratne December 17, 2018

The New Agents: Management of Experienced Patients and Resistance. Joel E. Gallant, MD, MPH Johns Hopkins University School of Medicine

Rapid Review Response HIV Medication and Depression

The use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines

Adherence Strategies for Older Adults. AIDS Community Research Initiative of America (ACRIA)

British HIV Association Guidelines for the Management of Hepatitis Viruses in Adults Infected with HIV 2013 Appendix 2

An Update on HIV Therapy Protease Inhibitors for Treatment Experienced Patients

HIV Treatment Guidelines

HIV associated CNS disease in the era of HAART

PrE-Exposure Prophylaxis (PrEP) A Tool at Your Hand to Fight HIV

INDEX. indications...11 initiation of metabolic and morphologic complications

Overview of HIV. Christina Polyak, MD, MPH. Research Physician. U.S. Military HIV Research Program, Walter Reed Army Institute of Research

TB Intensive Tyler, Texas December 2-4, Tuberculosis and HIV Co-Infection. Lisa Y. Armitige, MD, PhD. December 4, 2008.

HIV epidemiology since HIV in the United States. HIV Transmission

TB/HIV Co-Infection. Tuberculosis and HIV

Transcription:

THE HIV LIFE CYCLE Understanding How Antiretroviral Medications Work

DEFINITIONS Host: The animal or cell that another organism lives in. In HIV human CD4 T-cells are the host for HIV. Nucleus: The core of CD4 T-cells, it contains human DNA.

DEFINITIONS DNA: The chemical make-up of living things. DNA contains 2 copies of information. RNA: the chemical make up of living things. RNA contains only 1 copy of information and needs another copy to replicate. HIV: A virus that can only survive in host cells. It carries with it RNA, but must make DNA to replicate.

DEFINITIONS Retrovirus: A type of virus that has RNA instead of DNA as its genetic material. It uses an enzyme called reverse transcriptase to become part of the host cell s DNA. This allows many copies of the virus to be made in the host cell.

DNA versus RNA

OVERVIEW Several steps must occur for the HIV to replicate Entry of virus into host cell Copying RNA into DNA Hiding HIV DNA in host cell nucleus Multiplication of the virus within cell Budding of virus

ATTACHMENT HIV binds to receptors on CD4 T-cell A message is sent to the CD4 T-cell to let the virus in

FUSION Once bound, the virus is allowed to dump its contents into the CD4 T- cell Included in its contents are HIV RNA and reverse transcriptase

REVERSE TRANSCRIPTION The HIV RNA is turned into double-stranded DNA within the CD4 T- cell The enzyme reverse transcriptase aids in this process

INTEGRATION Once the DNA is formed, it hides itself in the human DNA housed in the CD4 T-Cell nucleus

TRANSCRIPTION Copies of HIV DNA are made and released from the nucleus in small packages Each of the small packages contains information for creating a new HIV

ASSEMBLY The protease enzyme in the cell combines the DNA packages to create active virus

BUDDING Once the new HIV is formed, it pushes itself out of the CD4 T-cell The virus steals part of the CD4 T-cells protective coating

Viral Life Cycle - The Big Picture (CD and Handout)

HIV Virus is in the bloodstream but also hides in other cells (e.g. lymph nodes) Drugs don t reach these sequestered cells* That s why there is no cure Virus destroys CD4 cells which lead to: Immune suppression Opportunistic infections and AIDS *HIV hides in cells in certain organs which are protected by the body: lymph nodes, the brain, reproductive organs. Not enough meds can get to those cells.

HOW MEDICATIONS WORK: Drug Classes and Medications

FUSION INHIBITORS Inhibit first step of HIV replication Prevent fusion of HIV to CD4 T-cell Virus is prevented from using host for replication Enfuviritide (Fuzeon )-BID Maraviroc (Selzentry )-BID

NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NNRTIs) Inhibit reverse transcriptase the enzyme responsible for turning HIV RNA into DNA Prevents virus from replicating Delavirdine (Rescriptor )-3x daily Nevirapine (ViramuneXR )-daily Efavirenz (Sustiva )-daily Etravirine (Intelence )-2x daily Rilpivirine (Edurant )-daily

NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NRTIs) Inhibit reverse transcriptase. Drug binds to the enzyme at a different place than the NNRTIs Lamivudine (Epivir )-1 to BID Zidovudine (Retrovir )-BID Abacavir (Ziagen )-1 to BID Emtricitabine (Emtriva )-daily Didanosine (VidexEC )-1 to BID Tenofovir (Viread )- daily Stavudine (Zerit )-BID Tenofovir + Emtricitabine (Truvada ) -daily Abacavir + Lamivudine (Epizom )- daily Zidovudine+ Lamivudine (Combivir )- BID Abacavir + Zidovudine + Lamivudine (Trizivir )- BID

INTEGRASE INHIBITORS Newest class of drugs that work within the cell nucleus. Blocks viral DNA and keeps HIV from binding to the host cell DNA. Prevents viral replication. Raltegravir (Isentress) 1 to BID

PROTEASE INHIBITORS Prevent the piecing together of HIV DNA into small packages Prevents formation of new HIV Fosamprenavir (Lexiva )-1 to BID Indinavir (Crixivan )-1 to 3x Saquinavir (Invirase, Fortovase )-BID Lopinavir + Ritonavir (Kaletra )-daily Atazanavir (Reyataz )-daily Nelfinavir (Viracept )-2 to 3x Tipranavir (Aptivus )- BID Ritonavir(Norvir )-1 to bid Prezista (Darunavir )- 1 to bid

SINGLE TABLET REGIMENS Efavirenz + Tenofovir + Emtricitabine (Atripla )- daily Rilpivirine + Tenofovir + Emtricitabine (Complera )- daily Elvitegravir + Cobicistat + Tenofovir + Emtricitabine (Stribild )- daily

GOALS OF THERAPY Suppress HIV VL to <50 copies/ml for as long as possible Improve quality of life Preserve medications for future use Restore immune function

PRINCIPLES OF HAART HIV has 1 goal: replication Triple-drug therapy Block virus in several different ways Slow down viral replication Allow immune system to recover